Full Press Release Details
IDEAYA Biosciences Announces Option and License Agreement for Potential First in Class B7H3 PTK7 Topo I Payload Bispecific ADC Program with Biocytogen.
IDYA
IDEAYA Biosciences Announces Option and License Agreement for Potential First in Class B7H3 PTK7 Topo I Payload Bispecific ADC Program with Biocytogen
Key Takeaway: IDEAYA Biosciences Announces Option and License Agreement for Potential First in Class B7H3 PTK7 Topo I Payload Bispecific ADC Program with Biocytogen
Price reaction · baseline $42.25 (2024-07-30 close) · hit after-hours · clean, no other IDYA news in the window
day 0 close · peak
+1.9%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma